Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Indolent Lymphoma Clinical Trial

Official title:
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145

Status Active, not recruiting

Clinical Trial Summary

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive - Copanlisib IV: day 1, 8, 15 every 28 days - Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only - Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)

Clinical Trial Description

Patients with relapsed/refractory lymphoma generally have few if any curative options and demonstrate poor response rates to standard salvage therapies. Novel regimens utilizing molecular targets are needed to improve outcomes in this patient population. While studies evaluating single agent small-molecule inhibitors have demonstrated activity in this setting, combinations of these drugs are generally thought to be more efficacious due to targeting separate mechanisms of action and decreased chance of developing resistance. The PD-1/PD-L1 axis is a molecular target that has been demonstrated to be up-regulated in several tumors including malignant lymphoma. Several pre-clinical studies have demonstrated the importance of this axis on clinical outcomes of patients afflicted with low grade lymphoma including FL. Targeting this axis with specific inhibitors would appear to be a rationale way to improve outcomes in patients afflicted with these diseases. PI3K inhibitors in addition to inhibiting signaling, impart changes in the immune cells in the tumor microenvironment and would appear to be a logical candidate to explore in combination with immunotherapy. Based on these preliminary data, we believe that we have justification for proceeding with our proposed phase I study to combine the PD-1 inhibitor, nivolumab, with the PI3K inhibitor, copanlisib, and the CD20 antibody, rituximab, in patients with relapsed/refractory follicular and marginal zone lymphoma. This work has the potential to provide a novel strategy to improve upon the clinical response noted in this patient population. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04431635
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	June 15, 2020
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03261349` - Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma	Phase 2
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Recruiting	`NCT05003141` - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Phase 1
Recruiting	`NCT00687778` - 11C-Acetate PET/CT Non-FDG-Avid Tumors	N/A
Recruiting	`NCT05543070` - Low-dose Radiotherapy in iNHL	Phase 2
Completed	`NCT00980395` - Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	Phase 2
Recruiting	`NCT04957693` - Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period	N/A
Terminated	`NCT00954005` - Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03424603` - Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies	Phase 1
Completed	`NCT01263899` - A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies	Phase 2
Recruiting	`NCT05020678` - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers	Phase 1
Active, not recruiting	`NCT04806035` - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.